BHF-177: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Entranced98 (talk | contribs) Importing Wikidata short description: "Chemical compound" |
||
(9 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = 462336838 |
| verifiedrevid = 462336838 |
||
| IUPAC_name = N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine |
| IUPAC_name = N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine |
||
| image = BHF- |
| image = BHF-177 Structure.svg |
||
<!--Clinical data--> |
<!--Clinical data-->| tradename = |
||
⚫ | |||
| tradename = |
|||
| |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
⚫ | |||
⚫ | |||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|||
⚫ | |||
| |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
||
| |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
⚫ | |||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 73Q4TVR90S |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!-- |
<!--Chemical data-->| chemical_formula = |
||
| C = 19 |
|||
⚫ | |||
| H = 20 |
|||
⚫ | |||
| F = 3 |
|||
⚫ | |||
| N = 3 |
|||
⚫ | |||
| smiles = Cc3nc(N[C@@H]2C[C@H]1CC[C@@H]2C1)c(cn3)c4ccc(cc4)C(F)(F)F |
|||
| excretion = |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| InChI = 1/C19H20F3N3/c1-11-23-10-16(13-4-6-15(7-5-13)19(20,21)22)18(24-11)25-17-9-12-2-3-14(17)8-12/h4-7,10,12,14,17H,2-3,8-9H2,1H3,(H,23,24,25)/t12-,14+,17+/m0/s1 |
|||
| InChIKey = ADHZHPOKTRHZGT-DXCKQFNABE |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Chemical data--> |
|||
| chemical_formula = |
|||
| C=19 | H=20 | F=3 | N=3 |
|||
| molecular_weight = 347.377 g/mol |
|||
| smiles = C4CC2CC4CC2Nc1nc(C)ncc1-c3ccc(C(F)(F)F)cc3 |
|||
}} |
}} |
||
'''BHF-177''' is a compound used in scientific research which acts as a [[Allosteric regulation#Pharmacology|positive allosteric modulator]] at the [[GABA B receptor|GABA<sub>B</sub>]] [[Receptor (biochemistry)|receptor]].<ref>{{cite journal | |
'''BHF-177''' is a compound used in scientific research which acts as a [[Allosteric regulation#Pharmacology|positive allosteric modulator]] at the [[GABA B receptor|GABA<sub>B</sub>]] [[Receptor (biochemistry)|receptor]].<ref>{{cite journal | vauthors = Guery S, Floersheim P, Kaupmann K, Froestl W | title = Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors | journal = Bioorganic & Medicinal Chemistry Letters | volume = 17 | issue = 22 | pages = 6206–11 | date = November 2007 | pmid = 17884493 | pmc = 2278029 | doi = 10.1016/j.bmcl.2007.09.023 }}</ref> It was shown to reduce self-administration of [[nicotine]] in animal studies.<ref name="pmid18445779">{{cite journal | vauthors = Paterson NE, Vlachou S, Guery S, Kaupmann K, Froestl W, Markou A | title = Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 326 | issue = 1 | pages = 306–14 | date = July 2008 | pmid = 18445779 | pmc = 2574924 | doi = 10.1124/jpet.108.139204 }}</ref> |
||
== References == |
== References == |
||
{{Reflist|2}} |
{{Reflist|2}} |
||
{{GABAergics}} |
{{GABAergics}} |
||
[[Category:Pyrimidines]] |
[[Category:Pyrimidines]] |
||
[[Category: |
[[Category:Trifluoromethyl compounds]] |
||
[[Category:GABAB receptor positive allosteric modulators]] |
[[Category:GABAB receptor positive allosteric modulators]] |
||
{{nervous-system-drug-stub}} |
{{nervous-system-drug-stub}} |
Latest revision as of 23:04, 1 April 2023
Identifiers | |
---|---|
| |
CAS Number | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H20F3N3 |
Molar mass | 347.385 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
BHF-177 is a compound used in scientific research which acts as a positive allosteric modulator at the GABAB receptor.[1] It was shown to reduce self-administration of nicotine in animal studies.[2]
References
[edit]- ^ Guery S, Floersheim P, Kaupmann K, Froestl W (November 2007). "Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6206–11. doi:10.1016/j.bmcl.2007.09.023. PMC 2278029. PMID 17884493.
- ^ Paterson NE, Vlachou S, Guery S, Kaupmann K, Froestl W, Markou A (July 2008). "Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats". The Journal of Pharmacology and Experimental Therapeutics. 326 (1): 306–14. doi:10.1124/jpet.108.139204. PMC 2574924. PMID 18445779.